GET DAILY SIGNALSWhy Is Carlsmed (CARL) Stock Up +19.78% Today?
Key Takeaways
- +19.78% surge: Shares of CARL jumped roughly 20% intraday to about $17.62, up from a prior close of $14.71.
- Primary catalyst: A wave of analyst price-target increases followed the company's beat-and-raise third-quarter earnings report.
- Strong fundamentals: Q3 revenue rose about 65% year over year, and management lifted its full-year revenue guidance.
- Secondary drivers: Elevated short interest and a breakout toward 52-week highs likely amplified the upward move.
- Broader context: The rally was largely company-specific rather than a broad-market or sector-wide move.
- What's next: Traders are watching product launches, reimbursement traction, and whether the rally holds above prior resistance.
- For deeper analysis, explore Price Targets, Earnings, and Forecast pages on Tickeron.
- Discover the strongest AI-driven trading strategies right now by visiting Trending AI Robots.
Opening Summary
Carlsmed, Inc. (CARL), a commercial-stage medical technology company that provides AI-enabled personalized spine surgery solutions through its aprevo platform, saw its shares surge on Wednesday. The stock climbed approximately 19.78% to about $17.62, up from the previous session's close of $14.71, as investors reacted to a series of bullish analyst actions following a stronger-than-expected quarterly report.
Analyst Price-Target Increases Drive the Rally
The most immediate trigger for the price rally was a coordinated round of upward price-target revisions from Wall Street firms. Truist Securities maintained its Buy rating and raised its target to $23 from $20, while Needham kept a Buy rating and lifted its target to $22 from $17. BTIG also reiterated a Buy and raised its target to $26 from $24, citing strong execution and improving commercial momentum. The analyst upgrades reinforced confidence in the company's growth trajectory and gave traders a clear catalyst to chase the stock higher.
Beat-and-Raise Earnings Results
Underpinning the analyst enthusiasm was a strong third-quarter report. Carlsmed posted revenue of approximately $21.6 million, up about 65% year over year and well ahead of consensus estimates near $19.5 million. The non-GAAP loss per share of $0.34 also beat expectations for a loss of roughly $0.41. Gross margin reached 77.3%, and management raised its full-year 2026 revenue guidance to a range of $78 million to $80 million, up from a prior range of $74 million to $78 million. The earnings-driven move reflected both the size of the top-line beat and the upward revision to guidance.
Operating Momentum and Product Catalysts
Beyond the headline numbers, investors focused on underlying demand indicators. The surgeon user base expanded more than 60% year over year, and procedure volume climbed sharply. The company's newer cervical product line grew to roughly 12% of revenue, complementing its established lumbar platform. Carlsmed also highlighted new Medicare reimbursement codes that took effect in October, along with the launch of its aprevo Lumbar Bilateral Posterior System, factors that analysts see supporting adoption and future revenue growth.
Market Context and Trading Activity
The move in CARL stood out as a company-specific event rather than a reflection of broad market or sector strength. The surge pushed the shares toward and beyond prior 52-week highs, a technical breakout that often attracts momentum buyers. With notable short interest in the stock, the sharp advance may also have been amplified by short covering. Trading activity picked up as the analyst revisions circulated, though the rally was driven primarily by the earnings follow-through rather than a single headline.
What Comes Next for CARL
Looking ahead, investors will be watching whether CARL can sustain its gains and build on the product and reimbursement catalysts announced alongside earnings. Key focus areas include the ramp of the cervical plating launch, the impact of the new reimbursement codes on hospital adoption, and the pace of surgeon and procedure growth. Risks include ongoing cash burn, widening GAAP losses, and potential competitive entry into the custom-implant market. The company remains unprofitable on a GAAP basis, so the path to operating leverage will remain central to the investment debate.
Trending AI Robots
Tickeron offers hundreds of AI trading bots that cover thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore automated approaches tailored to different market environments. To see which AI-driven strategies are currently leading the market, visit Trending AI Robots.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CARL saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for CARL moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 17 similar instances where the indicator exited the overbought zone. In 16 of the 17 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CARL as a result. In 23 of 26 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
CARL moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CARL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
CARL broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CARL entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for CARL just turned positive on October 22, 2026. Looking at past instances where CARL's MACD turned positive, the stock continued to rise in 9 of 11 cases over the following month. The odds of a continued upward trend are 82%.
The 10-day moving average for CARL crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 6 of 9 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +6.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where CARL advanced for three days, in 59 of 72 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.706) is normal, around the industry mean (4.477). P/E Ratio (-6.214) is within average values for comparable stocks, (13.414). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (6.596) is also within normal values, averaging (6.065).
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. CARL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CARL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement